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Abstract
Background: Myasthenic symptoms can be present in patients with amyotrophic lateral sclerosis (ALS). These
symptoms have been considered to be caused by the degeneration of distal motor neurons and the
neuromuscular junction (NMJ). Recent studies suggested that antibody to low-density lipoprotein receptor-related
protein 4 (LRP4) was a pathogenic agent of myasthenia gravis (MG), and it was also detected in ALS patients.
Case presentation: Patient 1: A 58-year-old Japanese man developed progressive weakness and subsequent
myasthenic symptoms including oculomotor disturbance. Clinical examination and electrophysiological studies
confirmed upper and lower motor neuron involvement and NMJ dysfunction, and anti-LRP4 antibody was detected
in his serum. A series of immunotherapies, including steroid pulse therapy, intravenous immunoglobulin, and
plasmapheresis, was performed, and the myasthenic symptoms partially improved. The titer of anti-LRP4 antibody
subsequently decreased. However, the therapeutic effect was transient, and ALS symptoms progressed. His clinical
findings fulfilled the criteria of probable ALS using the Awaji criteria. Patient 2: A 74-year-old Japanese man suffered
from progressive weakness of all limbs and dropped head in the evening. He complained of diplopia with a lateral
horizontal gaze. Probable ALS was diagnosed because of the upper and lower motor neuron signs, whereas anti-
LRP4 antibody was detected. Several immunotherapies were administered, and the myasthenic symptoms partially
responded to each therapy. However, the truncal muscle weakness progressed, and he died of respiratory failure.
Conclusion: We report two anti-LRP4 antibody-seropositive ALS patients with myasthenia who were not typical of
ALS patients, and showed partial responses to immunotherapies. The anti-LRP4 antibody-seropositive status may
influence developing ALS and cause additional ALS symptoms.
Keywords: Case report, Amyotrophic lateral sclerosis, Myasthenic symptom, Myasthenia gravis, Anti-LRP4 antibody,
Immunotherapy, Luciferase immunoprecipitation systems
* Correspondence: y-noto@koto.kpu-m.ac.jp
1Department of Neurology, Kyoto Prefectural University of Medicine
Graduate School of Medical Science, 465 Kajii-cho, Kamigyo-ku, Kyoto
602-0841, Japan
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Takahashi et al. BMC Neurology  (2016) 16:229 
DOI 10.1186/s12883-016-0758-1
Background
Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease in which the selective degeneration of
the upper and lower motor neuronal system causes
muscle weakness, atrophy, cramp, and fasciculation
combined with spasticity. The mechanism of neurode-
generation in sporadic ALS remains unclear. Although
various hypotheses have been put forward, including
glutamate-mediated excitotoxicity, protein aggregation,
apoptosis, astrocyte dysfunction, mitochondrial dysfunc-
tion, increased oxidative stress, and axonal ion channel
dysfunction, an autoimmune mechanism has been
proposed [1].
Patients with ALS occasionally present with
myasthenia-like symptoms such as increased muscle
fatigability. Myasthenia-like symptoms are thought to
be attributed to dysfunction of the neuromuscular
junction (NMJ) due to distal collateral branching
after axonal loss [2, 3]. On the other hand, symp-
toms in patients with myasthenia gravis (MG) are
caused by autoantibodies to the NMJ. There are two
established pathogenic autoantibodies for MG: an
anti-acetylcholine receptor (AchR) antibody, and a
muscle-specific tyrosine kinase (MuSK) antibody.
Both AchR and MuSK are essential components of
the NMJ, and their dysfunction and injury due to
autoantibodies cause NMJ dysfunction, leading to
myasthenia [4].
Recently, an autoantibody to low-density lipoprotein
receptor-related protein 4 (LRP4) was detected in the
serum of some MG patients [5, 6]. LRP4 is a component
of the NMJ as well as AChR and MuSK and is also indis-
pensable for NMJ formation and maintenance [7, 8].
Moreover, it has been demonstrated that anti-LRP4 anti-
body is a directly pathogenic agent causing MG [9]. Re-
garding ALS, Tzartos et al. reported that anti-LRP4
antibodies were detected in the serum and cerebrospinal
fluid (CSF) of patients with ALS, and suggested that the
antibody may be more broadly associated with damage
to LRP4-expressing tissues, such as motor neurons and
the NMJ [10]. However, the pathogenic role of anti-
LRP4 antibodies remains unclear in ALS. Here, we de-




The patient was a 58-year-old, right-handed man who
was admitted to our hospital. At 57 years of age, he de-
veloped dysarthria and weakness of the fingers on the
right hand. A few months prior to admission, he started
to experience leg muscle cramps and occasionally no-
ticed diplopia during lateral gaze. The severity of
diplopia and dysarthria fluctuated within a day and on
a daily basis. He had a history of cervical spondylosis
with no surgical treatment. His family history was
unremarkable.
On neurological examination, the abducent ocular
movement was incomplete bilaterally. Moreover, he had
dysarthria and mild tongue atrophy with fasciculation.
His hand muscles showed atrophy with weakness on
the right side, with Medical Research Council (MRC)
grade 4/5. Although there was no apparent atrophy of
other muscles, fasciculations were observed bilaterally
in the upper and lower limbs and trunk muscles. The
grip strength on the right side was weaker than that on
the left (34 and 35 kg, respectively). He could not
maintain a raised head for 90 s in a supine position
because of the progressive fatigability of neck muscles.
Sensory examination revealed nothing of note. Deep
tendon reflexes were normal, whereas the Wartenberg
reflex was present bilaterally. The edrophonium test
revealed moderate improvements of his dysarthria
and ocular movement impairment, whereas the
hand muscle weakness on the right side showed no
improvement. A routine nerve conduction study (NCS)
revealed nothing of note except for prolonged distal
latency in the right median nerve, and repetitive nerve
stimulation testing (RNST) of the ulnar, facial, and
accessory nerves also yielded results within normal
limits. On electromyography (EMG), fibrillation
potentials and polyphasic motor unit potentials
were detected in the right first dorsal interossei (FDI)
and right biceps brachii muscles, and fasciculation
potentials (FPs) were observed in the right trapezius,
FDI, biceps brachii, vastus lateral, and tibialis anterior
(TA) muscles. Stimulated-single fiber electromyography
(s-SFEMG) showed increased jitter in the right extensor
digitrum communis (EDC) muscle. On motor-evoked
potential (MEP) testing recorded at the abductor
hallucis (AH) muscle, the motor action potential was
typically evoked on the left but not on the right side.
Serological examination revealed that anti-AChR and
anti-MuSK antibodies were negative. Head magnetic
resonance imaging (MRI) showed a laminar high-
intensity lesion along the left motor cortex on
susceptibility-weighted imaging, which indicated
iron deposition. Cervical MRI revealed cervical
spondylosis at the C4/5/6/7/Th1 level, as well as mild
compression of the spinal cord at the C4/5 level with
no myelomalacia.
Abundant fasciculations in EMG and MEP and MRI
findings suggesting upper motor neuron dysfunction
indicated a diagnosis of ALS, whereas his ocular
movement dysfunction, fatigability of neck muscles,
and results of the edrophonium test were consistent
with a diagnosis of MG. A few weeks following
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admission, anti-LRP4 antibody was positive (antibody
index (A.I.): 1.08) using the luciferase immunoprecipita-
tion systems (LIPS) [5]. In this report, the antibody
levels are expressed as A.I., calculated as follows:
A:I: ¼ ½measurement value of the sample serum
relative luminescence unitsð Þ=
cut−off value relative luminescence unitsð Þ½ :
The normal value established for healthy individuals
is <1.0 [5]. Therefore, we started immunotherapy while
considering his condition to be immune-mediated. Ini-
tially, steroid pulse therapy (methylprednisolone at
1000 mg per day for 3 days) was conducted. The dys-
arthria and neck muscle fatigability partially improved,
and the frequency of fasciculations decreased through-
out his body. The quantitative myasthenia gravis
(QMG) score improved from 11 points before to 6
points after treatment [11]. Four weeks after the treat-
ment, his symptoms progressed again. Subsequently,
treatments with oral corticosteroids, intravenous
immunoglobulin, and plasmapheresis therapy were per-
formed. The ocular movements, diplopia, and dysarth-
ria improved mildly and transiently by each treatment,
and the titer of anti-LRP4 antibody normalized after
these treatments (A.I.: 0.67). However, all immunother-
apies had limited effects, and weakness and fatigability
progressed gradually. Six months after admission,
muscle atrophy and weakness of the left hand and both
legs developed, and his grip strength decreased (right:
21 kg, left: 11 kg). In addition, a bilateral Babinski sign
appeared 12 months after admission. A follow-up EMG
study showed the spread of active denervations of the
limbs. At that time, he fulfilled the diagnostic category
of probable ALS using the Awaji criteria [12, 13]. The
clinical course is shown in Fig. 1a.
Patient 2
A 74-year-old Japanese right-handed man was admitted
to hospital with weakness of the right hand and both
legs and a dropped head. Ten months before admission,
he was aware of clumsiness and suffered painful cramps
of his right hand. His dropped head aggravated in the
evening. He had no previous history of diplopia or dys-
phagia. His previous medical and family histories were
unremarkable.
On neurological examination, he presented with
diplopia with a horizontal gaze to the right side for
over 15 s. He had no dysarthria, and no tongue
abnormality. His grip strength on the right side was
lower than that on the left (28 and 32 kg, respectively).
He had mild weakness of MRC grade 4/5 and atrophy
of the right upper limb, neck, paraspinal, and
abdominal muscles. Fasciculations were extensively
observed in the limbs and truncal muscles. The deep
tendon reflexes were increased in the upper and lower
limbs. Sensory examination was normal. The
edrophonium test demonstrated the improvement of
diplopia, but muscle weakness remained unchanged.
NCS and RNST revealed decreased compound muscle
action potential amplitudes in the right abductor
pollicis brevis (APB) and FDI muscles with normal
conduction velocities and a 10.6% decrement in the
right ADM muscle on 3-Hz stimulation, respectively.
Increased jitter was also seen in s-SFEMG recorded at
the right EDC muscle. In EMG performed on the right
side, FPs were detected in the trapezius, paraspinal, and
upper and lower limbs muscles, and fibrillation poten-
tials or positive sharp waves were identified in the FDI,
paraspinal, and tibialis anterior muscles. Reduced re-
cruitment with high-amplitude motor unit potentials
was also observed in the trapezius, FDI, and vastus
lateralis muscles. On MEP testing of the AH muscles,
the central motor conduction time was prolonged on
the right side. In the serological test, anti-AChR and
anti-MuSK antibodies were negative. Brain MRI was
normal, and whole-spine MRI showed mild lumbar
spondylosis.
The patient was diagnosed with probable ALS using
the Awaji criteria, whereas the fluctuation of his
dropped head symptom and diplopia after loading were
not consistent with the diagnosis of ALS, but suggested
Fig. 1 The clinical course of anti-low-density lipoprotein receptor-
related protein 4 antibody-seropositive amyotrophic lateral sclerosis
patients with myasthenic symptoms. a patient 1, b patient 2
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a diagnosis of MG. A few weeks after admission,
anti-LRP4 antibody in serum was positive (A.I.: 1.50)
based on LIPS.
As in patient 1, steroid pulse therapy was conducted. A
few days after the therapy, the frequency of clinical
fasciculations and FPs on EMG decreased. However,
fatigability of the upper limb and neck muscles
worsened, and decrement at the right trapezius muscle
was newly detected in the follow-up RNST. The QMG
score worsened from 9 to 12 points. This clinical course
was thought to represent an initial escalation of MG at
that time. Subsequently, we conducted plasmapheresis
therapy. Fatigability improved, and the decrease in the
RNST was reduced after this therapy, but auto-LRP4
antibody remained positive (A.I.: 1.15). Six months after
admission, dyspnea due to respiratory muscle weakness
developed, and he died 7 months after admission. Clin-
ical examination just prior to his death revealed mild
muscle weakness of MRC grade 4/5 of the neck and
limbs, without tongue muscle atrophy or dysphagia.
His clinical course is shown in Fig. 1b.
Conclusion
We encountered two anti-LRP4 antibody-seropositive
patients who were consistent with the diagnostic criteria
and clinical course of ALS with some myasthenic symp-
toms that were partially improved by immunotherapies.
Although Mulder et al. reported four ALS patients with
a myasthenia-like symptom, the symptom was only mus-
cular fatigability involving the limbs [14]. Oculomotor
dysfunction in ALS was also previously reported [15].
However, the specific symptoms reported were pursuit
movement and saccadic impairments. Myasthenic symp-
toms in our two patients were different from those in
these previous reports. Our patients developed de-
creased ocular motility and showed the marked fluctu-
ation of symptoms within a day and on a daily basis.
These symptoms are uncommon in ALS and were par-
tially improved by immunotherapies. Therefore, their
myasthenic symptoms may have been partly immune-
mediated.
Regarding the association between ALS and other
autoimmune disorders, Turner et al. reported that the
risk of ALS was increased in people with prior auto-
immune diseases [16]. In addition, several autoantibodies
have been detected in the serum of ALS patients and
they may modify neurological symptoms of ALS [17–19].
Although our patients did not have prior symptoms
suggestive of MG, it is possible that they had subclinical
immunodeficiency and anti-LRP4 antibody may have
caused additional symptoms after the onset of ALS in
the context of the progression of axonal loss. Of further
relevance, the co-occurrence of ALS and MG is rare but
can develop [20, 21]. In those reports, some patients
developed myasthenic symptoms after the onset of ALS
symptoms, similarly to our patients, although they were
anti-AChR antibody-seropositive. These findings indicate
that a common immunological pathway involving the
NMJ may influence the clinical course of some ALS
patients.
LRP4 is one of the essential components of the NMJ,
and it binds to neural agrin and MuSK protein, leading
to AChR clustering and muscle excitation [22]. The
pathogenesis of anti-LRP4 antibody has been studied in
the presence of MG, and its detection rate in double-
seronegative MG patents was 9.4% in a previous study
with a large cohort [23]. On the other hand, Tzartos
et al. reported that anti-LRP4 antibody was detected in
the serum and CSF of sporadic ALS patients at 23.4% of
the detection rate in the serum of ALS patients [10].
Consequently, the pathological significance and mechan-
ism of production of anti-LRP4 antibody in neuromus-
cular disorders remain unclear. However, based on the
previous study by Shen et al. [9], anti-LRP4 antibody
may cause immunotherapy-responsive myasthenic symp-
toms in ALS patients.
In ALS, some experimental and pathological studies
reported that NMJ degeneration was observed in the
earliest stage of the disease, and this change may be the
origin of the disease pathogenesis [3, 24]. As such, the
clinical courses of our two patients indicate that an anti-
LRP4 antibody-seropositive status may influence devel-
oping ALS and occasionally cause additional symptoms
in the form of myasthenic symptoms.
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